Investors & Media

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat central nervous system (CNS) diseases. Minerva’s proprietary compounds include: MIN-101, which has entered Phase 3 clinical  development for schizophrenia; Seltorexant (MIN-202 or JNJ 42847922), which is in Phase 2b clinical development for insomnia and MDD; MIN-117, which is planned to enter Phase 2b clinical development for MDD in early 2018; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”

 

We are committed to providing investors access to current and historical information about Minerva Neurosciences, Inc., including news regarding product development programs, key shareholder updates and financial reports.